Celestial is a biopharmaceutical company focused on the development and commercialization of first in class of a new class of novel and groundbreaking lipid and mRNA therapeutics & vaccines for the treatment and prevention of a variety of infectious diseases, inflammatory conditions and cancers. Celestial’s lead therapeutic, CT-02 has been shown to be effective in binding/inactivating and killing a broad spectrum of pathogens.
Celestial’s lipid therapeutics are dual modal, broad spectrum anti-infectives with potent anti-inflammatory activity and offer a very unique opportunity to treat, prevent and cure a variety of infections and inflammatory conditions with a single therapeutic agent. Celestial is initially focusing on developing its lead lipid therapeutic platform to treat and prevent respiratory infections and inflammatory conditions that currently have limited or no treatment options and high unmet medical needs.
